CINECA IRIS Institutional Research Information System

ORLANDI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.208
AS - Asia 3.293
EU - Europa 2.929
SA - Sud America 422
AF - Africa 167
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 15.031
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.041
SG - Singapore 1.095
IT - Italia 926
CN - Cina 871
HK - Hong Kong 487
DE - Germania 466
SE - Svezia 439
BR - Brasile 352
VN - Vietnam 317
GB - Regno Unito 194
BG - Bulgaria 188
FR - Francia 173
FI - Finlandia 136
CA - Canada 125
TR - Turchia 105
IN - India 96
RU - Federazione Russa 84
JP - Giappone 74
UA - Ucraina 71
CI - Costa d'Avorio 67
AT - Austria 59
BD - Bangladesh 39
KR - Corea 35
PL - Polonia 30
NL - Olanda 29
BE - Belgio 28
CH - Svizzera 28
NG - Nigeria 25
ID - Indonesia 21
MX - Messico 21
PK - Pakistan 21
AR - Argentina 19
IQ - Iraq 19
SA - Arabia Saudita 19
SN - Senegal 19
MA - Marocco 15
ZA - Sudafrica 15
EC - Ecuador 14
UZ - Uzbekistan 14
ES - Italia 13
CO - Colombia 12
VE - Venezuela 12
CZ - Repubblica Ceca 11
PH - Filippine 10
AU - Australia 9
JO - Giordania 9
DK - Danimarca 8
LT - Lituania 8
IR - Iran 7
IE - Irlanda 6
PS - Palestinian Territory 6
EG - Egitto 5
GR - Grecia 5
MY - Malesia 5
NP - Nepal 5
TW - Taiwan 5
AL - Albania 4
CL - Cile 4
CR - Costa Rica 4
ET - Etiopia 4
HU - Ungheria 4
JM - Giamaica 4
KH - Cambogia 4
LB - Libano 4
NO - Norvegia 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BB - Barbados 3
BJ - Benin 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
KE - Kenya 3
PY - Paraguay 3
RO - Romania 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
HR - Croazia 2
IL - Israele 2
MD - Moldavia 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
Totale 15.021
Salva come PNG Salva come JPEG
Città #
Woodbridge 833
Ashburn 821
Singapore 618
Fairfield 612
Ann Arbor 603
San Jose 529
Hong Kong 478
Dallas 467
Houston 460
Chandler 458
Santa Clara 426
Seattle 304
Wilmington 255
Cambridge 232
Serra 218
Shanghai 193
Sofia 187
Beijing 183
New York 151
Milan 146
Los Angeles 123
Boardman 114
Munich 102
Ottawa 85
Princeton 84
Ho Chi Minh City 77
Lawrence 75
Lauterbourg 74
Medford 69
Abidjan 67
Tokyo 66
Council Bluffs 65
Jacksonville 63
Hanoi 61
Dong Ket 60
Des Moines 59
Pisa 59
London 55
Dearborn 53
Florence 51
Izmir 50
Vienna 49
Turku 46
Frankfurt am Main 45
Hefei 44
Buffalo 39
Istanbul 38
Nanjing 38
Rome 37
Helsinki 32
Seoul 32
Ogden 31
São Paulo 31
Redondo Beach 30
Boulder 29
Brussels 28
Columbus 28
San Diego 28
Düsseldorf 27
The Dalles 27
Falls Church 24
Fuzhou 24
Lagos 24
Bremen 23
Nanchang 23
Warsaw 22
Bern 20
Dakar 19
Marseille 19
Lucca 18
Pune 18
Redwood City 18
Da Nang 16
Stockholm 15
Nürnberg 14
Montreal 13
Orem 13
Phoenix 13
Quanzhou 13
Shenyang 13
Lancaster 12
Rho 12
Boston 11
Denver 11
Hebei 11
Kunming 11
Norwalk 11
Nuremberg 11
Tashkent 11
Toronto 11
Vicopisano 11
Jüchen 10
Rio de Janeiro 10
Seacroft 10
Atlanta 9
Baltimore 9
Belo Horizonte 9
Chennai 9
Guangzhou 9
Mumbai 9
Totale 10.914
Salva come PNG Salva come JPEG
Nome #
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 409
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 298
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy 284
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. 267
VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 255
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 254
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 250
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 249
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 247
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 246
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 243
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 243
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study 240
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients 240
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 235
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients 213
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 211
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo 209
The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. 207
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 205
Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. 201
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. 194
Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy 194
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 192
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 186
Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib 181
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 179
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination 177
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 172
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 172
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy 171
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 168
Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter 168
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. 167
Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib ( C ) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results 166
In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists 165
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 163
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 163
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 162
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 156
Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer 155
Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma 155
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells 154
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer 149
Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation 148
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions 148
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 148
Agenti melanocortinici per l’impiego nel trattamento terapeutico del melanoma, dei tumori del tratto gastroenterico e del carcinoma tiroideo 148
Prevention of capecitabine toxicity using a 5-FU test dose 147
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. 145
Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 145
In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma 144
Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors 143
IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration 142
A new biometric tool for three-dimensional subcutaneous tumor scanning in mice. 141
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report 140
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) 140
Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer 140
MELANOCORTIN AGENTS FOR USE IN THE THERAPEUTIC TREATMENT OF MELANOMA, TUMORS OF THE GASTROINTESTINAL TRACT, AND THYROID CARCINOMA 134
Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer 132
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation 130
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. 128
null 127
Antiangiogenic drugs in NASH: Evidence of a possible new therapeutic approach 127
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma 126
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients 126
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients 124
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis. 124
Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells 124
Vascular endothelial growth factor-A (VEGF-A) single nucleotide polymorphisms and endometriosis: still a controversial issue 123
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 123
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) 120
Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer 119
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids 118
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 117
Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases 114
null 114
null 114
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma 114
Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer 111
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients 110
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. 109
Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase 108
Correction to: Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy 106
Polimorfismi genetici del VEGF e DMLE 105
null 101
Metronomic Chemotherapy in Elderly Patients 95
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward 90
null 89
null 76
Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-fluorouracil Antitumor Activity In Vitro and In Vivo 71
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer 71
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells 54
Melanocortin-4 Receptor Antagonism Inhibits Colorectal and Anaplastic Thyroid Cancer In Vitro and In Vivo 49
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway 46
null 46
GABAergic signaling in colorectal cancer: Mechanistic insights, tumor microenvironment crosstalk, and therapeutic opportunities 42
Mathematical analysis of metronomic chemotherapy response in metastatic gastrointestinal cancer: identifying critical parameters from clinical data 34
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway 33
Digital Microneedles for Multiplexed Transdermal Sensing via Fluorescent QR Codes 29
Totale 15.287
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.131
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021172 0 0 0 0 0 0 0 0 0 0 51 121
2021/2022917 14 71 21 32 154 154 26 34 53 40 54 264
2022/20231.467 175 223 126 128 158 187 9 104 259 6 80 12
2023/2024850 82 97 93 56 101 167 26 48 18 22 53 87
2024/20252.993 17 114 43 192 302 325 228 126 302 390 331 623
2025/20263.792 285 410 503 335 412 269 640 224 246 374 94 0
Totale 15.290